Anne C Ritter1,2, Candace M Kammerer3, Maria M Brooks1, Yvette P Conley4,5, Amy K Wagner2,5,6,7. 1. Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A. 2. Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A. 3. Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A. 4. Department of Health Promotion and Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A. 5. Safar Center for Resuscitation Research, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A. 6. Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A. 7. Center for Neuroscience at University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A.
Abstract
OBJECTIVE: Posttraumatic seizures (PTS) commonly occur following severe traumatic brain injury (sTBI). Risk factors for PTS have been identified, but variability in who develops PTS remains. Excitotoxicity may influence epileptogenesis following sTBI. Glutamate transporters manage glutamate levels and excitatory neurotransmission, and they have been associated with both epilepsy and TBI. Therefore, we aimed to determine if genetic variation in neuronal glutamate transporter genes is associated with accelerated epileptogenesis and increased PTS risk after sTBI. METHODS: Individuals (N = 253) 18-75 years of age with sTBI were assessed for genetic relationships with PTS. Single nucleotide polymorphisms (SNPs) within SLC1A1 and SLC1A6 were assayed. Kaplan-Meier estimates and log-rank statistics were used to compare seizure rates from injury to 3 years postinjury for SNPs by genotype. Hazard ratios (HRs) were estimated using Cox proportional hazards regression for SNPs significant in Kaplan-Meier analyses adjusting for known PTS risk factors. RESULTS: Thirty-two tagging SNPs were examined (SLC1A1: n = 28, SLC1A6: n = 4). Forty-nine subjects (19.37%) had PTS. Of these, 18 (36.7%) seized within 7 days, and 31 (63.3%) seized between 8 days and 3 years post-TBI. With correction for multiple comparisons, genotypes at SNP rs10974620 (SLC1A1) were significantly associated with time to first seizure across the full 3-year follow-up (seizure rates: 77.1% minor allele homozygotes, 24.8% heterozygotes, 16.6% major allele homozygotes; p = 0.001). When seizure follow-up began day 2 postinjury, genotypes at SNP rs7858819 (SLC1A1) were significantly associated with PTS risk (seizure rates: 52.7% minor allele homozygotes, 11.8% heterozygotes, 21.1% major allele homozygotes; p = 0.002). After adjusting for covariates, we found that rs10974620 remained significant (p = 0.017, minor allele versus major allele homozygotes HR 3.4, 95% confidence interval [CI] 1.3-9.3). rs7858819 also remained significant in adjusted models (p = 0.023, minor allele versus major allele homozygotes HR 3.4, 95%CI 1.1-10.5). SIGNIFICANCE: Variations within SLC1A1 are associated with risk of epileptogenesis following sTBI. Future studies need to confirm findings, but variation within neuronal glutamate transporter genes may represent a possible pharmaceutical target for PTS prevention and treatment. Wiley Periodicals, Inc.
OBJECTIVE:Posttraumatic seizures (PTS) commonly occur following severe traumatic brain injury (sTBI). Risk factors for PTS have been identified, but variability in who develops PTS remains. Excitotoxicity may influence epileptogenesis following sTBI. Glutamate transporters manage glutamate levels and excitatory neurotransmission, and they have been associated with both epilepsy and TBI. Therefore, we aimed to determine if genetic variation in neuronal glutamate transporter genes is associated with accelerated epileptogenesis and increased PTS risk after sTBI. METHODS: Individuals (N = 253) 18-75 years of age with sTBI were assessed for genetic relationships with PTS. Single nucleotide polymorphisms (SNPs) within SLC1A1 and SLC1A6 were assayed. Kaplan-Meier estimates and log-rank statistics were used to compare seizure rates from injury to 3 years postinjury for SNPs by genotype. Hazard ratios (HRs) were estimated using Cox proportional hazards regression for SNPs significant in Kaplan-Meier analyses adjusting for known PTS risk factors. RESULTS: Thirty-two tagging SNPs were examined (SLC1A1: n = 28, SLC1A6: n = 4). Forty-nine subjects (19.37%) had PTS. Of these, 18 (36.7%) seized within 7 days, and 31 (63.3%) seized between 8 days and 3 years post-TBI. With correction for multiple comparisons, genotypes at SNP rs10974620 (SLC1A1) were significantly associated with time to first seizure across the full 3-year follow-up (seizure rates: 77.1% minor allele homozygotes, 24.8% heterozygotes, 16.6% major allele homozygotes; p = 0.001). When seizure follow-up began day 2 postinjury, genotypes at SNP rs7858819 (SLC1A1) were significantly associated with PTS risk (seizure rates: 52.7% minor allele homozygotes, 11.8% heterozygotes, 21.1% major allele homozygotes; p = 0.002). After adjusting for covariates, we found that rs10974620 remained significant (p = 0.017, minor allele versus major allele homozygotes HR 3.4, 95% confidence interval [CI] 1.3-9.3). rs7858819 also remained significant in adjusted models (p = 0.023, minor allele versus major allele homozygotes HR 3.4, 95%CI 1.1-10.5). SIGNIFICANCE: Variations within SLC1A1 are associated with risk of epileptogenesis following sTBI. Future studies need to confirm findings, but variation within neuronal glutamate transporter genes may represent a possible pharmaceutical target for PTS prevention and treatment. Wiley Periodicals, Inc.
Authors: R Bullock; R M Chesnut; G Clifton; J Ghajar; D W Marion; R K Narayan; D W Newell; L H Pitts; M J Rosner; J W Wilberger Journal: Eur J Emerg Med Date: 1996-06 Impact factor: 2.799
Authors: J D Rothstein; M Dykes-Hoberg; C A Pardo; L A Bristol; L Jin; R W Kuncl; Y Kanai; M A Hediger; Y Wang; J P Schielke; D F Welty Journal: Neuron Date: 1996-03 Impact factor: 17.173
Authors: S Evelyn Stewart; Jesen A Fagerness; Jill Platko; Jordan W Smoller; Jeremiah M Scharf; Cornelia Illmann; Eric Jenike; Nadia Chabane; Marion Leboyer; Richard Delorme; Michael A Jenike; David L Pauls Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2007-12-05 Impact factor: 3.568
Authors: Pamela L Ferguson; Gigi M Smith; Braxton B Wannamaker; David J Thurman; E Elisabeth Pickelsimer; Anbesaw W Selassie Journal: Epilepsia Date: 2009-10-20 Impact factor: 5.864
Authors: Patrick M Kochanek; Travis C Jackson; Ruchira M Jha; Robert S B Clark; David O Okonkwo; Hülya Bayır; Samuel M Poloyac; Amy K Wagner; Philip E Empey; Yvette P Conley; Michael J Bell; Anthony E Kline; Corina O Bondi; Dennis W Simon; Shaun W Carlson; Ava M Puccio; Christopher M Horvat; Alicia K Au; Jonathan Elmer; Amery Treble-Barna; Milos D Ikonomovic; Lori A Shutter; D Lansing Taylor; Andrew M Stern; Steven H Graham; Valerian E Kagan; Edwin K Jackson; Stephen R Wisniewski; C Edward Dixon Journal: J Neurotrauma Date: 2019-02-01 Impact factor: 5.269
Authors: Deborah J Mi; Shilpy Dixit; Timothy A Warner; John A Kennard; Daniel A Scharf; Eric S Kessler; Lisa M Moore; David C Consoli; Corey W Bown; Angeline J Eugene; Jing-Qiong Kang; Fiona E Harrison Journal: Neurobiol Aging Date: 2018-08-07 Impact factor: 4.673
Authors: Fanuel T Hagos; Solomon M Adams; Samuel M Poloyac; Patrick M Kochanek; Christopher M Horvat; Robert S B Clark; Philip E Empey Journal: Exp Neurol Date: 2019-02-21 Impact factor: 5.330
Authors: Ruchira M Jha; Ava M Puccio; David O Okonkwo; Benjamin E Zusman; Seo-Young Park; Jessica Wallisch; Philip E Empey; Lori A Shutter; Robert S B Clark; Patrick M Kochanek; Yvette P Conley Journal: Neurocrit Care Date: 2017-04 Impact factor: 3.210
Authors: Solomon M Adams; Yvette P Conley; Amy K Wagner; Ruchira M Jha; Robert Sb Clark; Samuel M Poloyac; Patrick M Kochanek; Philip E Empey Journal: Pharmacogenomics Date: 2017-10-04 Impact factor: 2.533
Authors: Pavel Klein; Raymond Dingledine; Eleonora Aronica; Christophe Bernard; Ingmar Blümcke; Detlev Boison; Martin J Brodie; Amy R Brooks-Kayal; Jerome Engel; Patrick A Forcelli; Lawrence J Hirsch; Rafal M Kaminski; Henrik Klitgaard; Katja Kobow; Daniel H Lowenstein; Phillip L Pearl; Asla Pitkänen; Noora Puhakka; Michael A Rogawski; Dieter Schmidt; Matti Sillanpää; Robert S Sloviter; Christian Steinhäuser; Annamaria Vezzani; Matthew C Walker; Wolfgang Löscher Journal: Epilepsia Date: 2017-12-15 Impact factor: 5.864